TQH2722 Clinical TBD

Antibody Information

Entry ID	1387
INN	None
Status	Clinical
Drug code(s)	TQH2722
Brand name	None
mAb sequence source	mAb human
General Molecular Category	TBD
Format, general category	TBD
Format details	TBD
Isotype (Fc)	TBD
Light chain isotype	TBD
Linker	None
Ave. DAR	None
Conjugated/fused moiety	None
Discovery method/technology	None

Therapeutic information

Target(s)	IL-4R alpha
Indications of clinical studies	Seasonal Allergic Rhinitis, Chronic Sinusitis With or Without Nasal Polyps, Atopic dermatitis, Phase 1 in healthy volunteers
Primary therapeutic area	Immune-mediated / inflammatory disorders

Development stage information

Phase lengths*

*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).

Most advanced stage of development (global)	Phase 3
Status	Active
Start of clinical phase (IND filing or first Phase 1)	June 01, 2022
Start of Phase 2	June 15, 2023
Start of Phase 3	September 27, 2024
Date BLA/NDA submitted to FDA
Year of first approval (global)	None
Date of first US approval
INN, US product name	None
US or EU approved indications	None

Company information

Company	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. Ltd.
Licensee/Partner	None
Comments about company or candidate	NCT06552520 / CTR20242940 Phase 3 in AD started in Sep 2024. NCT06439381 Phase 2 in chronic sinusitis with or without nasal polyps due to start in June 2024. NCT06089278 Phase 2 in chronic sinusitis due to start in Nov 2023. NCT05970432 is a Phase 2 in atopic dermatitis. NCT05409326 a Phase I Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
Full address of company	No. 369 South Yuzhou Rd, Haizhou District, Lianyungang, Jiangsu Province, P. R. China 222062 Asia China https://www.cttq.com/en/contact/index.htm

Description/comment

TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway.

Additional information

Anticipated events	None
Factor(s) contributing to discontinuation	None